Abstract:Abstract Aims Over time, cardiovascular disease (CVD) deaths increasingly exceed those from malignancy among cancer survivors. However, the association of myocardial injury with long-term survival (beyond 3 years) in cancer patients has not been previously described. Methods and results The high-sensitivity cardiac troponin (hs-cTn) and morbidities databases from the National Health and Nutrition Examination Survey (1999–2004) were linked with the latest mortality dataset isolating records were respondents reported cancer diagnosis by a healthcare professional. Myocardial injury was then determined by elevated hs-cTn. A total of 16 225 560 weighted records (1058 unweighted) were included in this observational study, with myocardial injury identified in 14.2%. Those with myocardial injury had progressively worse survival at 5 (51.6 vs. 89.5%), 10 (28.3 vs. 76.0%), and 15 years (12.6 vs. 61.4%) compared with those without myocardial injury. After adjusting for baseline characteristics, those with myocardial injury had an adjusted hazard ratio (aHR) of 2.10 [95% confidence interval (CI) 2.09–2.10, P < 0.001] for all-cause mortality, 2.23 (2.22–2.24, P < 0.001) for cardiovascular mortality, and 1.59 (95% CI 1.59–1.60, P < 0.001) for cancer mortality compared with those without myocardial injury. Among patients with no pre-existing CVD, the hs-cTn I Ortho assay was a strong independent predictor of all-cause (aHR 6.29, 95% CI 6.25–6.33, P < 0.001), CVD (aHR 11.38, 95% CI 11.23–11.54, P < 0.001), and cancer (aHR 5.02, 95% CI 4.96–5.07, P < 0.001) mortalities. Conclusion As a marker for myocardial injury, hs-cTns were independently associated with worse long-term survival among cancer patients with a stronger relationship with all-cause, cardiovascular, and cancer mortalities using hs-cTn I Ortho assay.

What problem does this paper attempt to address?

This paper aims to explore the relationship between myocardial injury and long - term survival rate of cancer patients. Specifically, the study evaluates the impact of myocardial injury on all - cause death, cardiovascular death and cancer - specific death in cancer patients by analyzing the association between high - sensitivity cardiac troponin (hs - cTn) levels and long - term survival (more than 3 years) of cancer patients. The study utilized data from the National Health and Nutrition Examination Survey (NHANES) in the United States, which is a large, nationally representative database. The analysis was carried out by linking the high - sensitivity cardiac troponin and morbidity databases and combining with the latest mortality data set. ### Research Background With the progress of cancer treatment techniques, the survival rate of cancer patients has significantly increased, but as a result, cardiovascular diseases have become the main cause of death for many cancer survivors. Myocardial injury is relatively common in cancer patients, especially after chemotherapy, but its relationship with the long - term survival of cancer patients has not been fully described. ### Research Methods The study used NHANES data from 1999 to 2004, including a total of 16,225,560 weighted records (1058 unweighted records), among which 14.2% of the patients had myocardial injury. Myocardial injury was determined by an increase in high - sensitivity cardiac troponin levels. The Kaplan - Meier survival curve and Cox regression model were used to analyze the relationship between myocardial injury and long - term survival, and factors such as baseline characteristics and comorbidities were adjusted. ### Main Findings 1. **Myocardial Injury and Survival Rate**: - The survival rates of patients with myocardial injury at 5 years (51.6% vs. 89.5%), 10 years (28.3% vs. 76.0%) and 15 years (12.6% vs. 61.4%) were significantly lower than those of patients without myocardial injury. - After adjusting for baseline characteristics, the all - cause death hazard ratio (aHR) of patients with myocardial injury was 2.10 (95% CI 2.09 - 2.10, P < 0.001), the cardiovascular death hazard ratio was 2.23 (95% CI 2.22 - 2.24, P < 0.001), and the cancer death hazard ratio was 1.59 (95% CI 1.59 - 1.60, P < 0.001). 2. **Comparison of Different hs - cTn Detection Methods**: - Among them, when using the hs - cTn I detection method of Ortho Company, the risk association between myocardial injury and all - cause death (aHR 6.29, 95% CI 6.25 - 6.33, P < 0.001), cardiovascular death (aHR 11.38, 95% CI 11.23 - 11.54, P < 0.001) and cancer death (aHR 5.02, 95% CI 4.96 - 5.07, P < 0.001) was the strongest. 3. **Excluding Patients with Existing Cardiovascular Diseases**: - Even after excluding patients with existing cardiovascular diseases, myocardial injury was still associated with higher risks of all - cause death (aHR 1.84, 95% CI 1.84 - 1.84, P < 0.001), cardiovascular death (aHR 2.09, 95% CI 2.08 - 2.10, P < 0.001) and cancer death (aHR 1.02, 95% CI 1.01 - 1.02, P < 0.001). ### Conclusion As a marker of myocardial injury, it is independently associated with a reduced long - term survival rate of cancer patients, especially more closely associated with all - cause death, cardiovascular death and cancer death. These findings support the value of long - term monitoring programs in cancer survivors to identify high - risk subgroups and take corresponding preventive and treatment measures. However, the current evidence is not sufficient to support routine screening for myocardial injury in cancer survivors for early detection of adverse cardiovascular outcomes.

Association of myocardial injury with adverse long-term survival among cancer patients

Association between peak troponin level and prognosis among patients admitted to intensive cardiovascular care unit

Cardiovascular outcomes in acute coronary syndrome patients with cancer: a statewide population-linkage study

Subclinical elevation of high-sensitive troponin T levels at the convalescent stage is associated with increased 5-year mortality after ST-elevation myocardial infarction

Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA.

Role of Biomarkers of Myocardial Injury to Predict Adverse Outcomes in Hypertrophic Cardiomyopathy

Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors

Cardiovascular mortality in people with cancer compared to the general population: A systematic review and meta-analysis

Postoperative elevated cardiac troponin levels predict all-cause mortality and major adverse cardiovascular events following noncardiac surgery: A dose-response meta-analysis of prospective studies

Acute and Long-Term Outcomes of ST-Elevation Myocardial Infarction in Cancer Patients, a 'Real World' Analysis with 175,000 Patients

High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease

Association of N-terminal pro–brain natriuretic peptide with survival among US cancer survivors

High-Sensitivity Troponin-T and heart failure risk in individuals with suspected acute coronary syndrome

Temporal trends in short and long-term outcomes after percutaneous coronary interventions among cancer patients

Cardiological parameters predict mortality and cardiotoxicity in oncological patients

Assessment of the prognostic value of preoperative high-sensitive troponin T for myocardial injury and long-term mortality for groups at high risk for cardiovascular events following noncardiac surgery: a retrospective cohort study

High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.

Abstract WMP98: Elevated Troponin With and Without Myocardial Infarction in Acute Ischemic Stroke

A systematic review and meta-analysis evaluating the association of high sensitivity troponin levels with outcomes in patients with stable coronary artery disease

Trends in the prevalence of malignancy among patients admitted with acute heart failure and associated outcomes: a nationwide population-based study

ASSOCIATION OF N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE AND HIGH-SENSITIVITY TROPONIN WITH MORTALITY IN THE GENERAL POPULATION